U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Debrisoquine, ultrarapid metabolism of

MedGen UID:
373268
•Concept ID:
C1837157
•
Finding
Synonym: DEBRISOQUINE, ULTRARAPID METABOLISM OF
 
OMIM®: 124030; 608902

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  

Professional guidelines

PubMed

CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans.
Llerena A, Dorado P, Ramírez R, González I, Alvarez M, Peñas-Lledó EM, Pérez B, Calzadilla LR
Pharmacogenomics J 2012 Apr;12(2):176-83. Epub 2010 Dec 7 doi: 10.1038/tpj.2010.85. PMID: 21135868
Potential genetic causes of heterogeneity of treatment effects.
Goldstein DB, Need AC, Singh R, Sisodiya SM
Am J Med 2007 Apr;120(4 Suppl 1):S21-5. doi: 10.1016/j.amjmed.2007.02.004. PMID: 17403378
Venlafaxine serum levels and CYP2D6 genotype.
Veefkind AH, Haffmans PM, Hoencamp E
Ther Drug Monit 2000 Apr;22(2):202-8. doi: 10.1097/00007691-200004000-00011. PMID: 10774634

Recent clinical studies

Etiology

CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans.
Llerena A, Dorado P, Ramírez R, González I, Alvarez M, Peñas-Lledó EM, Pérez B, Calzadilla LR
Pharmacogenomics J 2012 Apr;12(2):176-83. Epub 2010 Dec 7 doi: 10.1038/tpj.2010.85. PMID: 21135868
Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A, Dorado P, Peñas-Lledó EM
Pharmacogenomics 2009 Jan;10(1):17-28. doi: 10.2217/14622416.10.1.17. PMID: 19102711
Potential genetic causes of heterogeneity of treatment effects.
Goldstein DB, Need AC, Singh R, Sisodiya SM
Am J Med 2007 Apr;120(4 Suppl 1):S21-5. doi: 10.1016/j.amjmed.2007.02.004. PMID: 17403378
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM, Raimundo S, Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol 2004 Jan;369(1):23-37. Epub 2003 Nov 15 doi: 10.1007/s00210-003-0832-2. PMID: 14618296
Populations and genetic polymorphisms.
Weber WW
Mol Diagn 1999 Dec;4(4):299-307. doi: 10.154/MODI00400299. PMID: 10671640

Diagnosis

Genotyping of the cytochrome P450 2D6 4469 C>T polymorphism using SimpleProbes.
Nielsen KA, Hansen EL, Gille S
Scand J Clin Lab Invest 2007;67(3):280-90. doi: 10.1080/00365510601039982. PMID: 17454842
Potential genetic causes of heterogeneity of treatment effects.
Goldstein DB, Need AC, Singh R, Sisodiya SM
Am J Med 2007 Apr;120(4 Suppl 1):S21-5. doi: 10.1016/j.amjmed.2007.02.004. PMID: 17403378
Populations and genetic polymorphisms.
Weber WW
Mol Diagn 1999 Dec;4(4):299-307. doi: 10.154/MODI00400299. PMID: 10671640
Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia.
Arthur H, Dahl ML, Siwers B, Sjöqvist F
J Clin Psychopharmacol 1995 Jun;15(3):211-6. doi: 10.1097/00004714-199506000-00010. PMID: 7635999

Therapy

CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.
Llerena A, Dorado P, Ramírez R, Calzadilla LR, Peñas-Lledó E, Álvarez M, Naranjo ME, González I, Pérez B; CEIBA Consortium of Ibero–American Network of Pharmacogenetics & Pharmacogenomics RIBEF
Pharmacogenomics 2013 Dec;14(16):1973-7. doi: 10.2217/pgs.13.181. PMID: 24279852
Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A, Dorado P, Peñas-Lledó EM
Pharmacogenomics 2009 Jan;10(1):17-28. doi: 10.2217/14622416.10.1.17. PMID: 19102711
Potential genetic causes of heterogeneity of treatment effects.
Goldstein DB, Need AC, Singh R, Sisodiya SM
Am J Med 2007 Apr;120(4 Suppl 1):S21-5. doi: 10.1016/j.amjmed.2007.02.004. PMID: 17403378
Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine.
Dalén P, Frengell C, Dahl ML, Sjöqvist F
Ther Drug Monit 1997 Oct;19(5):543-4. doi: 10.1097/00007691-199710000-00011. PMID: 9357099
Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline.
Nordin C, Bertilsson L
Clin Pharmacokinet 1995 Jan;28(1):26-40. doi: 10.2165/00003088-199528010-00004. PMID: 7712660

Prognosis

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A, Dorado P, Peñas-Lledó EM
Pharmacogenomics 2009 Jan;10(1):17-28. doi: 10.2217/14622416.10.1.17. PMID: 19102711
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM, Raimundo S, Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol 2004 Jan;369(1):23-37. Epub 2003 Nov 15 doi: 10.1007/s00210-003-0832-2. PMID: 14618296
Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication.
Cascorbi I
Eur J Clin Invest 2003 Nov;33 Suppl 2:17-22. doi: 10.1046/j.1365-2362.33.s2.3.x. PMID: 14641552
Molecular mechanisms of genetic polymorphisms of drug metabolism.
Meyer UA, Zanger UM
Annu Rev Pharmacol Toxicol 1997;37:269-96. doi: 10.1146/annurev.pharmtox.37.1.269. PMID: 9131254
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F
J Pharmacol Exp Ther 1995 Jul;274(1):516-20. PMID: 7616439

Clinical prediction guides

CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans.
Llerena A, Dorado P, Ramírez R, González I, Alvarez M, Peñas-Lledó EM, Pérez B, Calzadilla LR
Pharmacogenomics J 2012 Apr;12(2):176-83. Epub 2010 Dec 7 doi: 10.1038/tpj.2010.85. PMID: 21135868
Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A, Dorado P, Peñas-Lledó EM
Pharmacogenomics 2009 Jan;10(1):17-28. doi: 10.2217/14622416.10.1.17. PMID: 19102711
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM, Raimundo S, Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol 2004 Jan;369(1):23-37. Epub 2003 Nov 15 doi: 10.1007/s00210-003-0832-2. PMID: 14618296
Molecular mechanisms of genetic polymorphisms of drug metabolism.
Meyer UA, Zanger UM
Annu Rev Pharmacol Toxicol 1997;37:269-96. doi: 10.1146/annurev.pharmtox.37.1.269. PMID: 9131254
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F
J Pharmacol Exp Ther 1995 Jul;274(1):516-20. PMID: 7616439

Supplemental Content

Table of contents

    Genetic Testing Registry

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...